InterCure posts NIS 130M H1 2025 revenue

InterCure Ltd. furnished a Form 6-K that packages its first-half 2025 financial disclosure materials, including a press release, interim financial statements, and management’s discussion and analysis.

Rhea-AI Filing Summary

InterCure Ltd. furnished a Form 6-K that packages its first-half 2025 financial disclosure materials, including a press release, interim financial statements, and management’s discussion and analysis. The press release headline states that InterCure generated NIS 130 million in revenue in the first half of 2025 and reported positive operating cash flow, indicating that its core operations brought in more cash than they consumed over that period.

The accompanying exhibits include condensed consolidated unaudited interim financial statements and a detailed analysis of financial condition and results of operations as of and for the six months ended June 30, 2025, along with related XBRL data files.

FAQ

What key financial result did InterCure (INCR) highlight in this Form 6-K?

The Form 6-K includes a press release stating that InterCure reported NIS 130 million in revenue and positive operating cash flow for the first half of 2025.

What financial period is covered by InterCure’s interim statements in this filing?

The condensed consolidated unaudited interim financial statements cover InterCure’s financial position as of June 30, 2025 and its results for the six months then ended.

What documents are attached to InterCure’s (INCR) Form 6-K as exhibits?

The filing attaches a press release on first-half 2025 results, condensed consolidated unaudited interim financial statements as of June 30, 2025, and a detailed management’s discussion and analysis for the same six-month period, along with related XBRL data files.

Does the InterCure (INCR) Form 6-K include detailed income and cash flow statements?

Yes. The exhibits include condensed consolidated unaudited interim statements of financial position, profit or loss and other comprehensive income, changes in equity, and cash flows as part of the June 30, 2025 financial statements.

In what format does InterCure provide its financial data in this Form 6-K?

InterCure provides key financial information in both traditional financial statement format and in XBRL (Inline XBRL) format, covering its interim balance sheet, income statement, equity changes, and cash flows.

What does ‘positive operating cash flow’ mean for InterCure’s first half of 2025?

Positive operating cash flow means that, over the first half of 2025, InterCure’s day-to-day business activities generated more cash than they used, which generally supports liquidity and ongoing operations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/08/2025 - 08:50 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of October 2025

Commission File Number: 001-40614

INTERCURE LTD.

(Translation of registrant’s name into English)

85 Medinat ha-Yehudim Street

Herzliya, 4676670, Israel

Tel: +972 77 460 5012

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Report of Foreign Private Issuer on Form 6-K consists of InterCure Ltd.’s (the “Registrant”): (i) press release issued on October 8, 2025, titled “InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow,” which is attached hereto as Exhibit 99.1; (ii) Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2025, which is attached hereto as Exhibit 99.2; and (ii) Management’s Discussion and Analysis of Financial Condition and Results of Operations as of June 30, 2025, and for the Six Months then Ended, which is attached hereto as Exhibit 99.3.

Exhibit No.
99.1		Press Release issued by InterCure Ltd. on October 8, 2025, titled “InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow.”
99.2		InterCure Ltd.’s Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2025.
99.3		InterCure Ltd.’s Management’s Discussion and Analysis of Financial Condition and Results of Operation as of June 30, 2025, and for the Six Months then Ended.
101		The following financial information from the Registrant’s Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2025, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Unaudited Interim Statements of Financial Position, (ii) Condensed Consolidated Unaudited Interim Statements of Profit or Loss and Other Comprehensive Income, (iii) Condensed Consolidated Unaudited Interim Statements of Changes in Equity; (iv) Condensed Consolidated Unaudited Interim Statements of Cash Flows, and (v) Notes to Condensed Consolidated Unaudited Interim Financial Statements.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INTERCURE LTD.
Date: October 8, 2025	/s/ Amos Cohen
	Amos Cohen
	Chief Financial Officer